Group 1: ProGo® Product Overview - ProGo® is distinguished by its unique ability to activate GLP-1 and GIP receptors, supported by clinical studies demonstrating weight loss benefits [1] - ProGo® Bioactive Peptides optimize glucose and fat metabolism, enhancing energy levels and promoting a longer active lifestyle [2] Group 2: Company Background - Hofseth BioCare ASA is a Norwegian company focused on sustainability and optimal utilization of natural resources, upcycling byproducts from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo® (whole salmon oil), and CalGo® / NT-II™ (salmon bone powder) aimed at improving human and pet health [3] Group 3: Scientific Evidence and Partnerships - Hofseth BioCare emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, including improved iron metabolism and fat reduction in overweight adults with ProGo® [4] - OmeGo® has demonstrated immune health benefits, while CalGo® supports bone and joint health, contributing to healthy aging [4] Group 4: Biotech Ventures - Hofseth BioCare has established a biotech-focused spin-off, HBC Immunology, which has raised external finance and is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [4]

Group 1: ProGo® Product Overview - ProGo® is distinguished by its unique ability to activate GLP-1 and GIP receptors, supported by clinical studies demonstrating weight loss [1] - ProGo® Bioactive Peptides optimize glucose and fat metabolism, enhancing energy levels and promoting a longer active lifestyle [2] Group 2: Company Background - Hofseth BioCare ASA is a Norwegian company focused on sustainability and optimal utilization of natural resources, upcycling byproducts from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo® (whole salmon oil), and CalGo® / NT-II(TM) (salmon bone powder) aimed at improving human and pet health [3] Group 3: Scientific Evidence and Partnerships - Hofseth BioCare emphasizes scientific evidence, leading to academic partnerships and the identification of unique health benefits, including improved iron metabolism and fat reduction in overweight adults with ProGo® [4] - OmeGo® has demonstrated immune health benefits, while CalGo® supports bone and joint health, contributing to healthy aging [4] Group 4: Biotech Ventures - Hofseth BioCare has established a biotech-focused spin-off, HBC Immunology, which has raised external finance and is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]

Hofseth BioCare ASA held its Annual General Meeting on 23 May 2025. All proposals were resolved as presented in the notice issued on 2 May 2025. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: +47 936 32 966 E-mail: joo@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability ...

Core Insights - HBC reported total operating revenues of NOK 60.9 million in Q1 2025, a 15% increase from NOK 52.4 million in Q1 2024, driven by growth in higher-margin human and pet health segments despite production constraints and commodity oil market pressures [1][6] - The company experienced a significant increase in B2B sales in the human segment, with a 66% year-over-year growth, particularly for products like OmeGo® and ProGo® [6] - HBC launched an unsecured bond that closed after the quarter with subscriptions of approximately CHF 3.5 million, indicating strong investor interest [6] Financial Performance - Cost of goods sold (CoGS) rose to NOK 37.5 million from NOK 27.3 million in Q1 2024, while operating expenses slightly decreased to NOK 23.1 million from NOK 23.9 million [2] - EBITDA for the quarter was negative NOK 19.9 million, compared to NOK -16.2 million in Q1 2024, with operational EBITDA at NOK -8.3 million [3] - The first quarter included NOK 3.0 million in one-time restructuring costs aimed at improving long-term operational efficiency [2][3] Product and Market Developments - HBC's product offerings include ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [5] - The company achieved a record production period at its Midsund facility, operating 15-20% above its rated capacity while maintaining quality [6] - Clinical studies have shown that OmeGo® significantly reduces coughing and improves sleep in individuals exposed to pollution, while NT-II™ demonstrated improvements in joint pain and stiffness [6][7] Strategic Initiatives - HBC is expanding its production capacity at Berkåk to triple output, reflecting confidence in future demand [6] - The company has made significant advances in pharmaceutical research, including programs targeting prostate cancer and asthma, and has established a biotech-focused spin-off, HBC Immunology [7] - HBC participated in major industry events, reinforcing its leadership in marine-based nutrition and expanding its market presence [6]

Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon in the US. Branded as “Norwegian Salmon Oil”, it retains the complete balance and nutritional profile of fresh Atlantic salmon in a softgel format. Joining Garden of Life’s portfolio of health supplements available online, Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-grade salmon and provides whole-fish health benefits from its full spectrum of omegas. It differentiates from a competitive Omega-3 ...

Group 1: Bond Issuance - The company has successfully placed CHF-denominated unsecured bonds totaling approximately CHF 3.5 million, subscribed by investors in Switzerland and Liechtenstein [2] - The settlement of the bond issue is expected to occur on 5 May 2025, and the bonds will not be listed on any stock exchange or trading venue [2] - The bonds have a term of three years, maturing on 30 April 2028, with an interest rate of 10% per annum and quarterly interest payments starting on 30 September 2025 [3] Group 2: Corporate Purpose and Financial Details - The net proceeds from the bond issuance will be used for general corporate purposes [2] - The bonds are callable at par value at quarterly intervals, with the first call option available on 30 June 2026 [3] Group 3: Company Overview - Hofseth BioCare ASA is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [3] - The company upcycles side streams of the salmon industry into health-improving ingredients such as ProGo®, OmeGo®, and CalGo® / NT-II((TM)) [3][4] - Hofseth BioCare emphasizes scientific evidence and has established academic partnerships to identify unique health benefits, including improved iron metabolism and immune health [4] Group 4: Research and Development - The company has received patents for its discoveries and has spun out a biotech-focused company, HBC Immunology, which is developing therapeutics for prostate and ovarian cancer, as well as a therapy for asthma [4]

The Annual General Meeting of Hofseth BioCare ASA for 2025 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 23 May 2025 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal ut ...